Fitness news and fitness widget

The neural commands sent by the brain to the arm when reaching out for an object were recently modeled using a theory that they are coordinated to minimize energy expenditure, according to a study released on October 23, 2008 in the open-access journal PLoS Computational Biology. Neuroscientists have studied many aspects of how actions are coordinated by the brain.

Elderly women can increase muscle strength as much as young women can, a new study from the University of New Hampshire finds, indicating that decline in muscle function is less a natural part of the aging process than due to a decline in physical activity. The research, published in the journal medicine & Science in Sports & Exercise, compared strength gains of inactive elderly women and inactive young women after both groups participated in an eight-week training regime.

The European Medicines Agency (EMEA) says the authorization that was granted two years ago to Sanofi-Aventis to market its anti-obesity drug Acomplia (rimonabant) in the Eropean Union (EU) should be suspended because the drug's advantages don't outweigh the potential disadvantages which include a doubling of the risk of developing psychiatric disorders such as depression when compared with placebo.

When I was a kid, my grandfather and I watched Miss America every year. We would root for Miss Tennessee to win and my grandfather would inevitably say, "You...

The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Acomplia (rimonabant) from Sanofi-Aventis. The EMEA's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Acomplia no longer outweigh its risks and the marketing authorisation should be suspended across the European Union (EU).

Thursday 23 October 2008, London GlaxoSmithKline (GSK) announced today that alli (orlistat 60 mg) has received a positive opinion as a non-prescription product from the Committee for Medicinal Products for Human Use (CHMP). This means the product will now be proposed for final approval by the European Commission and marketing authorisation could be granted in the coming months.

Sanofi-aventis announced today that the European Medicines Agency (EMEA) has recommended to the European Commission (EC) the temporary suspension of the marketing authorisation of Acomplia(R) (rimonabant) for the approved indication of overweight and obese patients. Acomplia(R) has been marketed in 18 EU countries since 2006 and has provided significant clinical benefits to patients suffering from obesity and overweight with associated co-morbidities.

New research continues to link tart cherries, one of today's hottest "Super Fruits," to lowering risk factors for heart disease. In addition to lowering cholesterol and reducing inflammation, the study being presented by University of Michigan researchers at next week's American Dietetic Association annual meeting, found that a cherry-enriched diet lowered body weight and fat - major risk factors for heart disease.

According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings. Tesofensine can produce weight loss twice that of currently approved obesity drugs, and should be studied in phase III trials.